摘要
目的:探讨自体多种细胞因子诱导的杀伤细胞(CIK)输注同步化疗紫杉醇治疗上皮性卵巢癌患者的综合治疗方法,观察安全性和临床疗效。方法:分析2011年11月-2013年11月在本院接受自体CIK细胞输注同步联合紫杉醇治疗的上皮性卵巢癌患者17例。检测治疗前后患者淋巴细胞亚群和血清细胞因子的变化,观察其临床疗效和不良反应。结果:治疗过程中未出现明显治疗相关不良反应,评估后客观有效率(CR+PR)88%。治疗后外周血CD3+、CD3+CD8+、CD3+CD56+细胞比例较治疗前明显升高(P<0.05),CD3+CD4+比例和CD4+CD25+Treg细胞比例下降。治疗后血清中白介素-2(IL-2)、γ-干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)较治疗前明显上升(P<0.05)。结论:自体CIK细胞同步输注联合紫杉醇治疗上皮性卵巢癌,可改善患者免疫功能,提高患者Th1类细胞因子水平,是一种有前景的治疗上皮性卵巢癌治疗手段。
Objective： To investigate safety and preliminary clinical effects on epithelial ovarian cancer patients treated with autologous cytokine induced killers（CIK） synchronously combined paclitaxel.Method： 17 cases of epithelial ovarian cancer from November 2011 to November 2013 in our hospital were treated with CIK synchronously combined paclitaxel.The lymphocyte subgroup and Th1 type cytokines（IL-2、IFN-γ、TNF-α） level in serum were examined, the safety and clinical effects were also observed.Result：No obvious side effects occurred during and after treatments,the objective response rate was 88%. The levels of CD3^＋,CD3^＋CD8^＋ and CD3^＋CD56^＋ were significantly increased after treatment compared before treatment（P0.05）, while CD3^＋CD4^＋ and CD4^＋CD25^＋Treg were significantly decreased. The serum levels of IL-2, IFN-γ and TNF-α increased significantly after treatment（P0.05）.Conclusion： The autologous CIK synchronously combined paclitaxel can improve the immunological function and elicit Th1 immune responses, which encourage that the CIK is one of promising treatments for epithelial ovarian cancer.
出处
《中国医学创新》
CAS
2014年第33期150-153,共4页
Medical Innovation of China
